We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Prothrombin Time Derived from POC Test Compared to Laboratory Test

By LabMedica International staff writers
Posted on 17 Feb 2015
Prothrombin time/international normalized ratio (PT/INR) is used for dosing and monitoring oral anticoagulant therapy (OAT) based on warfarin, as the therapeutic range of warfarin is narrow and there is a considerable variation in inter- and intra-individual pharmacologic response.

One of the most widely used point-of-care (POC) devices to evaluate prothrombin time for monitoring oral anticoagulant therapy is unlike other laboratory methods, as it detects electrical signals produced by thrombin activity to derive the international normalized ratio (INR). More...


Scientists at Yonsei University College of Medicine (Seoul, Korea) collected 91 venous blood samples submitted for fibrinogen testing to the clinical laboratory. Platelet-poor plasma was obtained by centrifugation. The fibrinogen level was measured using Fibrinogen-C XL reagent (Instrumentation Laboratory; Milan, Italy) via Clauss method using ACL TOP (Beckman Coulter; Fullerton, CA, USA). Samples were selected after fibrinogen testing according to the fibrinogen level. PT INR was measured by both the laboratory method and CoaguChek XS (Roche Diagnostics; Mannheim, Germany).

The samples were stratified into low, mid, and high fibrinogen groups by fibrinogen levels of <130 mg/dL, 130–450 mg/dL, and >450 mg/dL, respectively. The mean INR difference of the low fibrinogen group was significantly different from that of the mid or high fibrinogen group. In the low fibrinogen group, CoaguChek XS INR showed a negative bias compared with the laboratory INR, while the mid and high fibrinogen groups had positive bias.

The authors concluded that that patient selection according to fibrinogen status should precede the implementation of POC testing using CoaguChek XS. Also, periodic comparisons between CoaguChek XS and laboratory INR results should be continued during the use of CoaguChek XS. The study was published on January 31, 2015, in the Journal of Clinical Laboratory Analysis.

Related Links:

Yonsei University College of Medicine
Instrumentation Laboratory
Roche Diagnostics



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.